JPMorgan Cuts PT on Zai Lab Limited (ZLAB) to $32 From $39

Core Insights - Zai Lab Limited (NASDAQ:ZLAB) is recognized as a high-growth healthcare stock, with JPMorgan reducing its price target from $39 to $32 while maintaining an Overweight rating [1] - The company reported a 17% year-over-year revenue growth to $127.6 million for fiscal Q4 2025 and a 15% year-over-year growth to $460.2 million for the full year 2025 [1] - Zai Lab's Zocilurtatug pelitecan (zoci) is expected to be the company's first global oncology launch, with three registration-enabling studies planned by the end of 2026 [1] Group 1: Financial Performance - Total revenues for fiscal Q4 2025 reached $127.6 million, reflecting a 17% increase year-over-year [1] - For the full year 2025, total revenues amounted to $460.2 million, marking a 15% year-over-year growth [1] Group 2: Product Pipeline and Development - Zai Lab is advancing a differentiated global pipeline that includes ZL-1503, ZL-6201, ZL-1222, and ZL-1311, with key regional programs progressing [2] - The company is preparing for the commercial launch of KarXT in China and anticipates pivotal data readouts for povetacicept in IgAN and elegrobart in TED by 2026 [2] Group 3: Company Overview - Zai Lab Limited is a biopharmaceutical company focused on developing therapies for unmet medical needs in areas such as autoimmune disorders, oncology, infectious diseases, and neuroscience [3] - The company's product portfolio includes Zejula, Optune, Qinlock, and Nuzyra [3]